Clinical Trial Update: A Study to Evaluate Further Therapeutic Strategies With Guselkumab in Participants With Moderate-to-Severe Plaque-Type Psoriasis [Phase 3]

View source ↗

Summary

Phase 3 study evaluating guselkumab in adults with moderate-to-severe plaque psoriasis has completed and posted results (May 10, 2023).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Psoriasis

Drugs mentioned

• TREMFYA (guselkumab)

Snippet

Sponsor: Janssen-Cilag International NV | Conditions: Psoriasis | Phase 3 | Status: COMPLETED | Results posted: 2023-05-10